Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcript
Addex Therapeutics Ltd held its Q4 2025 earnings call on April 30, 2026, to discuss full-year financial results and corporate updates. CEO Timothy Dyer and Head of Translational Science Mikhail Kalinichev provided insights into the company's financial performance and research and development progress. The company emphasized forward-looking statements based on current knowledge and directed participants to its website for official documents.
- ▪Addex Therapeutics Ltd conducted its Q4 2025 earnings call on April 30, 2026, at 10:00 AM EDT.
- ▪Timothy Dyer, Co-Founder and CEO, led the call and highlighted the release of financial statements and a press release available on the company’s website.
- ▪Mikhail Kalinichev, Head of Translational Science, provided an update on the company's R&D programs during the call.
- ▪The company included forward-looking statements and directed listeners to its disclaimers regarding future projections.
- ▪The earnings call was recorded and accessible via webcast for public participation.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4897032-addex-therapeutics-ltd-adxn-q4-2025-earnings-call-transcript"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
